相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Xing Huang et al.
AUTOPHAGY (2019)
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
Valentina Martin et al.
BRITISH JOURNAL OF CANCER (2019)
Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
Guanggui Ding et al.
CANCER BIOLOGY & THERAPY (2019)
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1
Hui Li et al.
GASTROENTEROLOGY (2019)
Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
Xiaoting Lin et al.
CELL DEATH & DISEASE (2019)
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping
Wei Jin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
Toshio Fujino et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa et al.
CLINICAL CANCER RESEARCH (2019)
Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance
Zhipeng Su et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
Nichola Cruickshanks et al.
CLINICAL CANCER RESEARCH (2019)
miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
Cristina Migliore et al.
EMBO MOLECULAR MEDICINE (2018)
C-MET inhibitors for advanced non-small cell lung cancer
Giulia Pasquini et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Novel MET Exon 14 Skipping Treatment-Naive Lung Adenocarcinoma Presented Primary Resistance to Crizotinib
Wenjuan Jiang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
EGFR-TKIs resistance via EGFR-independent signaling pathways
Qian Liu et al.
MOLECULAR CANCER (2018)
Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Sofie Ellebaek Pollmann et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors
Meriem Sarah Mekki et al.
Oncotarget (2018)
Dysregulated HAI-2 Plays an Important Role in Renal Cell Carcinoma Bone Metastasis through Ligand-Dependent MET Phosphorylation
Koji Yamasaki et al.
CANCERS (2018)
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
Maria Apicella et al.
CELL METABOLISM (2018)
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Lars-Arne Berger et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer
S. Baldacci et al.
REVUE DES MALADIES RESPIRATOIRES (2018)
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Federica Papaccio et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer
Magda Bahcall et al.
CLINICAL CANCER RESEARCH (2018)
Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
Nicole Glodde et al.
IMMUNITY (2017)
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer
Floriana Morgillo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
Sai-Hong Ignatius et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping
Alexa B. Schrock et al.
Journal of Thoracic Oncology (2017)
Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping
Yu Zhang et al.
LUNG CANCER (2017)
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
Thanyanan Reungwetwattana et al.
LUNG CANCER (2017)
A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor
Weitao Shen et al.
CELL DEATH & DISEASE (2017)
被撤回的出版物: Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma (Retracted article. See vol. 13, 2022)
Paola Bendinelli et al.
CELL DEATH & DISEASE (2017)
Targeting ALK: Precision Medicine Takes on Drug Resistance
Jessica J. Lin et al.
CANCER DISCOVERY (2017)
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
Zu-Jun Sun et al.
ONCOTARGET (2017)
Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells
Rebecca D. Schroeder et al.
ONCOTARGET (2017)
Helicobacter pylori CagA Protein Negatively Regulates Autophagy and Promotes Inflammatory Response via c-Met-PI3K/Akt-mTOR Signaling Pathway
Na Li et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
CAR T-cell immunotherapy of MET-expressing malignant mesothelioma
Thivyan Thayaparan et al.
ONCOIMMUNOLOGY (2017)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al.
CLINICAL CANCER RESEARCH (2017)
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
Anna Li et al.
CLINICAL CANCER RESEARCH (2017)
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer
So Yeong Ahn et al.
ANTICANCER RESEARCH (2017)
Non-Complicated Acute Appendicitis in Adults Treated Successfully by Conservative Treatment without Recurrences
Anestis Charalampopoulos et al.
CHIRURGIA (2017)
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
Stefani Spranger
INTERNATIONAL IMMUNOLOGY (2016)
Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor
Marc-Antoine Benderra et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations
Hua-Jie Dong et al.
LUNG CANCER (2016)
HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes
J. Cui et al.
ONCOGENE (2016)
Beta 1-integrin-c-Met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes
Rachel Barrow-McGee et al.
NATURE COMMUNICATIONS (2016)
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall et al.
CANCER DISCOVERY (2016)
Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
Ryan E. Henry et al.
ONCOTARGET (2016)
A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY plus E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx plus ) metastatic NSCLC.
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors
Ningfei An et al.
CANCER RESEARCH (2015)
c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers
Aijun Shen et al.
CANCER RESEARCH (2015)
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
Russell W. Jenkins et al.
CLINICAL LUNG CANCER (2015)
Targeting c-Met in Cancer by MicroRNAs: Potential Therapeutic Applications in Hepatocellular Carcinoma
Zeynep F. Karagonlar et al.
DRUG DEVELOPMENT RESEARCH (2015)
The role for autophagy in cancer
Eileen White
JOURNAL OF CLINICAL INVESTIGATION (2015)
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Giorgio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
Teppei Sugano et al.
MOLECULAR CANCER THERAPEUTICS (2015)
KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells
Dominic Leiser et al.
MOLECULAR ONCOLOGY (2015)
MET is required for the recruitment of anti-tumoural neutrophils
Veronica Finisguerra et al.
NATURE (2015)
MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway
Zhiqiang Zheng et al.
PLOS ONE (2015)
The STING pathway and the T cell-inflamed tumor microenvironment
Seng-Ryong Woo et al.
TRENDS IN IMMUNOLOGY (2015)
MET PROMOTES ANTITUMOR NEUTROPHIL RECRUITMENT AND CYTOTOXICITY
[Anonymous]
CANCER DISCOVERY (2015)
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
Paul K. Paik et al.
CANCER DISCOVERY (2015)
Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
Eunice L. Kwak et al.
CANCER DISCOVERY (2015)
Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
Fujian Ji et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer
Zheng Wu et al.
ONCOTARGET (2015)
Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
Consalvo Petti et al.
ONCOTARGET (2015)
Retinal Detachment Due to Retinal Dialysis: Surgical Outcome After Scleral Buckling
Sanaullah Jan et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2015)
METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET plus ) adenocarcinoma of the stomach or gastroesophageal junction (GEC)
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting c-Met in melanoma Mechanism of resistance and efficacy of novel combinatorial inhibitor therapy
Deven Etnyre et al.
CANCER BIOLOGY & THERAPY (2014)
MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bed-side
A. Avan et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy
Daniele Musiani et al.
FASEB JOURNAL (2014)
Hepatocyte Growth Factor Limits Autoimmune Neuroinflammation via Glucocorticoid-Induced Leucine Zipper Expression in Dendritic Cells
Mahdia Benkhoucha et al.
JOURNAL OF IMMUNOLOGY (2014)
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
J. Jean Cui
JOURNAL OF MEDICINAL CHEMISTRY (2014)
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition
Wei Zhou et al.
JOURNAL OF PATHOLOGY (2014)
Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence
Valentina Martin et al.
MOLECULAR ONCOLOGY (2014)
Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy
S. Gallo et al.
CELL DEATH & DISEASE (2014)
被撤回的出版物: Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification (Retracted article. See vol. 13, 2022)
P. Maroni et al.
CELL DEATH & DISEASE (2014)
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Friedhelm Bladt et al.
CANCERS (2014)
Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study.
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist
A. Fasolo et al.
ANNALS OF ONCOLOGY (2013)
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells
Magali Humbert et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Fibroblasts as architects of cancer pathogenesis
Timothy Marsh et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Targeting MET: why, where and how?
Elena Ghiso et al.
CURRENT OPINION IN PHARMACOLOGY (2013)
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
Yohei Funakoshi et al.
INVESTIGATIONAL NEW DRUGS (2013)
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease
Kadoaki Ohashi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells
Ying Liu et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Regulation of MET Kinase Inhibitor Resistance by Copy Number of MET in Gastric Carcinoma Cells
Yohei Funakoshi et al.
ONCOLOGY RESEARCH (2013)
The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity
Jea-Hyun Baek et al.
JOURNAL OF IMMUNOLOGY (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation
Nathan V. Lee et al.
PLOS ONE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
Fred Harbinski et al.
CANCER DISCOVERY (2012)
Hepatocyte growth factor-induced c-Src-phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway inhibits dendritic cell activation by blocking IκB kinase activity
Eshu Singhal et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Autophagy Induction with RAD001 Enhances Chemosensitivity and Radiosensitivity through Met Inhibition in Papillary Thyroid Cancer
Chi-Iou Lin et al.
MOLECULAR CANCER RESEARCH (2010)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells
Mahdia Benkhoucha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Crosstalk between the α2β1 integrin and c-met/HGF-R regulates innate immunity
Karissa D. Mccall-Culbreath et al.
BLOOD (2008)
Molecular cancer therapy: Can our expectation be MET?
Cristina Migliore et al.
EUROPEAN JOURNAL OF CANCER (2008)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
A novel role of hepatocyte growth regulator through suppressing factor as an immune dendritic cell function
K Okunishi et al.
JOURNAL OF IMMUNOLOGY (2005)
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
KA Furge et al.
ONCOGENE (2000)
分享论文
